<rst>
<header>
	<relations>
			<rel name="Analogy" type="multinuc"/>
			<rel name="Cause-Result" type="multinuc"/>
			<rel name="Comment-Topic" type="multinuc"/>
			<rel name="Comparison" type="multinuc"/>
			<rel name="Conclusion" type="multinuc"/>
			<rel name="Consequence" type="multinuc"/>
			<rel name="Contrast" type="multinuc"/>
			<rel name="Disjunction" type="multinuc"/>
			<rel name="Evaluation" type="multinuc"/>
			<rel name="Interpretation" type="multinuc"/>
			<rel name="Inverted-Sequence" type="multinuc"/>
			<rel name="List" type="multinuc"/>
			<rel name="Otherwise" type="multinuc"/>
			<rel name="Problem-Solution" type="multinuc"/>
			<rel name="Proportion" type="multinuc"/>
			<rel name="Question-Answer" type="multinuc"/>
			<rel name="Reason" type="multinuc"/>
			<rel name="Same-Unit" type="multinuc"/>
			<rel name="Sequence" type="multinuc"/>
			<rel name="Statement-Response" type="multinuc"/>
			<rel name="Temporal-Same-Time" type="multinuc"/>
			<rel name="TextualOrganization" type="multinuc"/>
			<rel name="Topic-Comment" type="multinuc"/>
			<rel name="Topic-Drift" type="multinuc"/>
			<rel name="Topic-Shift" type="multinuc"/>
			<rel name="analogy-e" type="rst"/>
			<rel name="analogy" type="rst"/>
			<rel name="antithesis-e" type="rst"/>
			<rel name="antithesis" type="rst"/>
			<rel name="attribution-e" type="rst"/>
			<rel name="attribution-n-e" type="rst"/>
			<rel name="attribution-n" type="rst"/>
			<rel name="attribution" type="rst"/>
			<rel name="background-e" type="rst"/>
			<rel name="background" type="rst"/>
			<rel name="cause-e" type="rst"/>
			<rel name="cause" type="rst"/>
			<rel name="circumstance-e" type="rst"/>
			<rel name="circumstance" type="rst"/>
			<rel name="comment-e" type="rst"/>
			<rel name="comment" type="rst"/>
			<rel name="comparison-e" type="rst"/>
			<rel name="comparison" type="rst"/>
			<rel name="concession-e" type="rst"/>
			<rel name="concession" type="rst"/>
			<rel name="conclusion-e" type="rst"/>
			<rel name="conclusion" type="rst"/>
			<rel name="condition-e" type="rst"/>
			<rel name="condition" type="rst"/>
			<rel name="consequence-n-e" type="rst"/>
			<rel name="consequence-n" type="rst"/>
			<rel name="consequence-s-e" type="rst"/>
			<rel name="consequence-s" type="rst"/>
			<rel name="contingency-e" type="rst"/>
			<rel name="contingency" type="rst"/>
			<rel name="definition-e" type="rst"/>
			<rel name="definition" type="rst"/>
			<rel name="elaboration-additional-e" type="rst"/>
			<rel name="elaboration-additional" type="rst"/>
			<rel name="elaboration-general-specific-e" type="rst"/>
			<rel name="elaboration-general-specific" type="rst"/>
			<rel name="elaboration-object-attribute-e" type="rst"/>
			<rel name="elaboration-object-attribute" type="rst"/>
			<rel name="elaboration-part-whole-e" type="rst"/>
			<rel name="elaboration-part-whole" type="rst"/>
			<rel name="elaboration-process-step-e" type="rst"/>
			<rel name="elaboration-process-step" type="rst"/>
			<rel name="elaboration-set-member-e" type="rst"/>
			<rel name="elaboration-set-member" type="rst"/>
			<rel name="enablement-e" type="rst"/>
			<rel name="enablement" type="rst"/>
			<rel name="evaluation-n-e" type="rst"/>
			<rel name="evaluation-n" type="rst"/>
			<rel name="evaluation-s-e" type="rst"/>
			<rel name="evaluation-s" type="rst"/>
			<rel name="evidence-e" type="rst"/>
			<rel name="evidence" type="rst"/>
			<rel name="example-e" type="rst"/>
			<rel name="example" type="rst"/>
			<rel name="explanation-argumentative-e" type="rst"/>
			<rel name="explanation-argumentative" type="rst"/>
			<rel name="hypothetical-e" type="rst"/>
			<rel name="hypothetical" type="rst"/>
			<rel name="interpretation-n-e" type="rst"/>
			<rel name="interpretation-n" type="rst"/>
			<rel name="interpretation-s-e" type="rst"/>
			<rel name="interpretation-s" type="rst"/>
			<rel name="manner-e" type="rst"/>
			<rel name="manner" type="rst"/>
			<rel name="means-e" type="rst"/>
			<rel name="means" type="rst"/>
			<rel name="otherwise-e" type="rst"/>
			<rel name="otherwise" type="rst"/>
			<rel name="preference-e" type="rst"/>
			<rel name="preference" type="rst"/>
			<rel name="problem-solution-n-e" type="rst"/>
			<rel name="problem-solution-n" type="rst"/>
			<rel name="problem-solution-s-e" type="rst"/>
			<rel name="problem-solution-s" type="rst"/>
			<rel name="purpose-e" type="rst"/>
			<rel name="purpose" type="rst"/>
			<rel name="question-answer-n-e" type="rst"/>
			<rel name="question-answer-n" type="rst"/>
			<rel name="question-answer-s-e" type="rst"/>
			<rel name="question-answer-s" type="rst"/>
			<rel name="reason-e" type="rst"/>
			<rel name="reason" type="rst"/>
			<rel name="restatement-e" type="rst"/>
			<rel name="restatement" type="rst"/>
			<rel name="result-e" type="rst"/>
			<rel name="result" type="rst"/>
			<rel name="rhetorical-question-e" type="rst"/>
			<rel name="rhetorical-question" type="rst"/>
			<rel name="statement-response-n-e" type="rst"/>
			<rel name="statement-response-n" type="rst"/>
			<rel name="statement-response-s-e" type="rst"/>
			<rel name="statement-response-s" type="rst"/>
			<rel name="summary-n-e" type="rst"/>
			<rel name="summary-n" type="rst"/>
			<rel name="summary-s-e" type="rst"/>
			<rel name="summary-s" type="rst"/>
			<rel name="temporal-after-e" type="rst"/>
			<rel name="temporal-after" type="rst"/>
			<rel name="temporal-before-e" type="rst"/>
			<rel name="temporal-before" type="rst"/>
			<rel name="temporal-same-time-e" type="rst"/>
			<rel name="temporal-same-time" type="rst"/>
			<rel name="topic-drift-e" type="rst"/>
			<rel name="topic-drift" type="rst"/>
			<rel name="topic-shift-e" type="rst"/>
			<rel name="topic-shift" type="rst"/>
		</relations>
</header>
<body>
		<segment id="1" parent="70" relname="TextualOrganization">MATERIALS AND METHODS</segment>
		<segment id="2" parent="71" relname="TextualOrganization">Study design</segment>
		<segment id="3" parent="72" relname="span">The present study was a 6-week , multicentre , open-label , randomized controlled trial</segment>
		<segment id="4" >conducted in patients</segment>
		<segment id="5" >recruited from the departments of psychiatry in 15 general hospitals in south India.</segment>
		<segment id="6" parent="73" relname="Topic-Drift">Approval for the study was obtained from the Drug Controller General of India as well as the ethics committees at each participating site.</segment>
		<segment id="7" parent="73" relname="Topic-Drift">The trial was registered at the Clinical Trials Registry of India.</segment>
		<segment id="8" parent="73" relname="Topic-Drift">Informed consent for participation in the study was obtained from each patient in writing.</segment>
		<segment id="9" parent="75" relname="TextualOrganization">Sample</segment>
		<segment id="10" parent="76" relname="span">The sample comprised consecutive consenting male and female patients ,</segment>
		<segment id="11" parent="10" relname="elaboration-object-attribute-e">aged 18-65 years ,</segment>
		<segment id="12" parent="77" relname="span">diagnosed with major depressive disorder</segment>
		<segment id="13" parent="12" relname="elaboration-object-attribute-e">that was at least 4 weeks in duration.</segment>
		<segment id="14" parent="81" relname="span">All patients were free from psychotropic medication for at least two weeks prior to randomization ,</segment>
		<segment id="15" parent="79" relname="span">and all scored at least 18</segment>
		<segment id="16" parent="15" relname="elaboration-object-attribute-e">(indicating at least moderate severity of illness)</segment>
		<segment id="17" parent="80" relname="span">on the Hamilton Rating Scale for Depression</segment>
		<segment id="18" parent="17" relname="elaboration-object-attribute-e">(HAM-D).</segment>
		<segment id="19" parent="88" relname="span">Patients were excluded</segment>
		<segment id="20" parent="84" relname="span">if they had any other major Axis I psychiatric disorder , any medical or neurological disorder</segment>
		<segment id="21" parent="20" relname="elaboration-object-attribute-e">that could influence the diagnosis or treatment of depression ,</segment>
		<segment id="22" parent="85" relname="span">any condition other than depression</segment>
		<segment id="23" parent="22" relname="elaboration-object-attribute-e">that was not on stable treatment for at least the past one month ,</segment>
		<segment id="24" parent="86" relname="span">any condition</segment>
		<segment id="25" parent="24" relname="elaboration-object-attribute-e">that could pose a health risk during a clinical trial ,</segment>
		<segment id="26" parent="87" relname="span">and any clinically significant abnormality or disorder</segment>
		<segment id="27" parent="26" relname="elaboration-object-attribute-e">that was newly detected during the baseline assessments.</segment>
		<segment id="28" parent="90" relname="span">Patients</segment>
		<segment id="29" parent="28" relname="elaboration-object-attribute-e">who were considered to be at risk of suicide</segment>
		<segment id="30" parent="89" relname="Same-Unit">were also excluded from participation in the study.</segment>
		<segment id="31" parent="93" relname="TextualOrganization">Treatment</segment>
		<segment id="32" parent="92" relname="span">Consenting patients</segment>
		<segment id="33" parent="32" relname="elaboration-object-attribute-e">who fulfilled the study selection criteria</segment>
		<segment id="34" parent="94" relname="span">were randomized 1:1 to receive open-label treatment with either PB extended release capsules</segment>
		<segment id="35" >(starting dose , 75 mg/day)</segment>
		<segment id="36" parent="96" relname="span">or sertraline tablets</segment>
		<segment id="37" parent="36" relname="elaboration-object-attribute-e">(starting dose , 50 mg/day).</segment>
		<segment id="38" parent="114" relname="elaboration-additional">All medications were dosed in the morning.</segment>
		<segment id="39" parent="97" relname="Comparison">PB was obtained from Indigent Pharma , Bogasapura , India ,</segment>
		<segment id="40" parent="97" relname="Comparison">and sertraline was purchased from commercial sources.</segment>
		<segment id="41" parent="99" relname="span">The dose of medication was flexibly uptitrated ,</segment>
		<segment id="42" parent="41" relname="manner-e">based on efficacy and tolerability ,</segment>
		<segment id="43" parent="98" relname="Same-Unit">at the discretion of the treating clinician.</segment>
		<segment id="44" parent="100" relname="span">Downtitration was also allowed</segment>
		<segment id="45" parent="44" relname="condition">if raised doses were not tolerated.</segment>
		<segment id="46" parent="102" relname="conclusion">Thus , treatment reflected real world practice.</segment>
		<segment id="47" parent="103" relname="elaboration-additional">The dosing range was 75-300 mg/day for PB and 50-200 mg/day for sertraline.</segment>
		<segment id="48" parent="104" relname="span">No other psychotropic medication was permitted during the study except for lorazepam at a maximum dose of 2 mg during a 24-h period</segment>
		<segment id="49" >to treat agitation or insomnia.</segment>
		<segment id="50" >At the end of the 6-week study , the trial medications were tapered and withdrawn.</segment>
		<segment id="51" parent="109" relname="span">Assessments Patients were assessed at baseline and , again , at 2-weekly intervals</segment>
		<segment id="52" parent="106" relname="span">using the HAM-D , the Montgomery-Asberg Rating Scale</segment>
		<segment id="53" parent="52" relname="elaboration-object-attribute-e">(MADRS) ,</segment>
		<segment id="54" parent="107" relname="span">and the Clinical Global Impression Scales for Severity and Improvement</segment>
		<segment id="55" parent="54" relname="elaboration-object-attribute-e">(CGI-S and CGI-I).</segment>
		<segment id="56" parent="108" relname="Comparison">Response was defined as 50 % or greater improvement in HAM-D scores ,</segment>
		<segment id="57" parent="108" relname="Comparison">and remission as a final HAM-D score of 10 or lower.</segment>
		<segment id="58" parent="118" relname="Topic-Drift">All adverse events were recorded.</segment>
		<segment id="59" parent="112" relname="span">Safety assessments included assessment of vital signs ,hematological measures , metabolic parameters , liver function tests , renal function tests , thyroid function tests , and the electrocardiogram</segment>
		<segment id="60" parent="59" relname="elaboration-object-attribute-e">(EKG).</segment>
		<segment id="61" parent="111" relname="Same-Unit">Statistical analysis</segment>
		<segment id="62" parent="113" relname="List">The primary outcome measure was the improvement in the HAM-D score after 6 weeks of treatment.</segment>
		<segment id="63" parent="113" relname="List">Secondary outcomes were post-baseline changes in MADRS ratings as well as safety measures.</segment>
		<segment id="64" parent="113" relname="List">Means were compared within groups</segment>
		<segment id="65" >using the paired t test and between groups</segment>
		<segment id="66" >using the independent sample t test.</segment>
		<segment id="67" parent="113" relname="List">Frequencies were compared between groups</segment>
		<segment id="68" >using the Chi square test.</segment>
		<segment id="69" parent="113" relname="List">Alpha for statistical significance was set at 0.05.</segment>
		<group id="70" type="multinuc" />
		<group id="71" type="multinuc" parent="70" relname="TextualOrganization"/>
		<group id="72" type="span" parent="74" relname="span"/>
		<group id="73" type="multinuc" parent="72" relname="elaboration-additional"/>
		<group id="74" type="span" parent="71" relname="TextualOrganization"/>
		<group id="75" type="multinuc" />
		<group id="76" type="span" parent="82" relname="Topic-Drift"/>
		<group id="77" type="span" parent="10" relname="elaboration-object-attribute-e"/>
		<group id="78" type="multinuc" parent="14" relname="elaboration-object-attribute-e"/>
		<group id="79" type="span" parent="78" relname="Same-Unit"/>
		<group id="80" type="span" parent="78" relname="Same-Unit"/>
		<group id="81" type="span" parent="82" relname="Topic-Drift"/>
		<group id="82" type="multinuc" parent="75" relname="TextualOrganization"/>
		<group id="83" type="multinuc" parent="19" relname="condition-e"/>
		<group id="84" type="span" parent="83" relname="List"/>
		<group id="85" type="span" parent="83" relname="List"/>
		<group id="86" type="span" parent="83" relname="List"/>
		<group id="87" type="span" parent="83" relname="List"/>
		<group id="88" type="span" parent="82" relname="Topic-Drift"/>
		<group id="89" type="multinuc" parent="82" relname="Topic-Drift"/>
		<group id="90" type="span" parent="89" relname="Same-Unit"/>
		<group id="91" type="multinuc" parent="114" relname="span"/>
		<group id="92" type="span" parent="91" relname="Same-Unit"/>
		<group id="93" type="multinuc" />
		<group id="94" type="span" parent="91" relname="Same-Unit"/>
		<group id="95" type="multinuc" parent="34" relname="elaboration-object-attribute-e"/>
		<group id="96" type="span" parent="95" relname="Comparison"/>
		<group id="97" type="multinuc" parent="114" relname="elaboration-additional"/>
		<group id="98" type="multinuc" parent="101" relname="span"/>
		<group id="99" type="span" parent="98" relname="Same-Unit"/>
		<group id="100" type="span" parent="101" relname="elaboration-additional"/>
		<group id="101" type="span" parent="102" relname="span"/>
		<group id="102" type="span" parent="103" relname="span"/>
		<group id="103" type="span" parent="116" relname="span"/>
		<group id="104" type="span" parent="117" relname="elaboration-additional"/>
		<group id="105" type="multinuc" parent="51" relname="manner"/>
		<group id="106" type="span" parent="105" relname="Same-Unit"/>
		<group id="107" type="span" parent="105" relname="Same-Unit"/>
		<group id="108" type="multinuc" parent="109" relname="elaboration-additional"/>
		<group id="109" type="span" parent="110" relname="span"/>
		<group id="110" type="span" parent="118" relname="Topic-Drift"/>
		<group id="111" type="multinuc" parent="118" relname="Topic-Drift"/>
		<group id="112" type="span" parent="111" relname="Same-Unit"/>
		<group id="113" type="multinuc" parent="119" relname="Topic-Drift"/>
		<group id="114" type="span" parent="117" relname="span"/>
		<group id="115" type="span" parent="119" relname="Topic-Drift"/>
		<group id="116" type="span" parent="114" relname="elaboration-additional"/>
		<group id="117" type="span" parent="120" relname="span"/>
		<group id="118" type="multinuc" parent="119" relname="Topic-Drift"/>
		<group id="119" type="multinuc" parent="93" relname="TextualOrganization"/>
		<group id="120" type="span" parent="115" relname="span"/>
  </body>
</rst>